Gel for rash from EGFR inhibitor cancer therapy
Part of Skin clinical trials.
This trial tests a new gel (TAR-0520) for treating a bothersome, acne-like rash that often occurs on the face, scalp, or upper chest during cancer treatment with cetuximab or panitumumab. The goal is to see if it helps reduce the rash without affecting your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic colorectal cancer and are being treated with cetuximab or panitumumab.
- You have a rash (folliculitis) caused by your EGFR inhibitor cancer treatment.
- You can apply the study gel yourself or have someone who can help.
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cream, ATR04-484, to see if it can help with skin rashes caused by certain cancer medications (EGFR inhibitors, KRAS inhibitors, or MEK inhibitors). If you have a moderate to severe rash on your face or other areas from these drugs, this trial may offer a new way to ease your symptoms.
This Phase 2 study tests a topical cream (HT-001) to treat skin rashes caused by EGFR inhibitors. It aims to see whether the cream is safe and can reduce rash symptoms and discomfort.
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
This trial tests whether extra care to prevent skin and infusion side effects helps people with advanced lung cancer who are getting amivantamab (with lazertinib or chemotherapy). It aims to make these treatments easier to tolerate.
This trial tests a gel applied to the skin that may help prevent nerve pain and numbness caused by common breast cancer chemotherapy drugs (paclitaxel and docetaxel). The goal is to see if the gel is safe and effective in reducing these side effects.
This trial tests a new targeted drug (cetuximab β) combined with radiation and chemotherapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new EGFR Inhibitor-associated Rash trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.